CoChat
Sign Up
Cited by 24

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Additive antileukemia effects by GFI1B- and BCR–ABL-specific siRNA in advanced phase chronic myeloid leukemic cells

Koldehoff, M, Zakrzewski, J L, Beelen, D W, Elmaagacli, A H·2013·Cancer Gene Therapy
DOI 10.1038/cgt.2013.31
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/cgt.2013.31

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Figures

Image 1
CC-BY-NC-ND · From the PDF
after transfection with BCR-ABL siRNA and GFI1B siRNA or scrambled siRNA or no siRNA (spontaneously)
after transfection with BCR-ABL siRNA and GFI1B siRNA or scrambled siRNA or no siRNA (spontaneously)CC-BY-NC-ND · From the PDF
Figure 1 Growth rate of K562 cells after transfection with BCR-ABL siRNA, GFI1B siRNA and cotreatment with both siRNAs as determined by the MTT assay. ( a ) Forty-eight hours after siRNA transfection, the number of viable K562 cells decreased significantly ( P o 0.0001). ( b ) Kinetics of growth inhibition of K562 cells following application of 175 pM GFI1B siRNA and 54 pM BCR-ABL siRNA or two scrambled siRNAs and/or without siRNAs is shown. Mean and s.d. are presented. The percentage of viable cells was determined by comparison with untreated or scrambled siRNA-transfected cells. BCR-ABL siRNA, breakpoint cluster region-Abelson murine leukemia oncogene small interfering RNA.
Figure 1 Growth rate of K562 cells after transfection with BCR-ABL siRNA, GFI1B siRNA and cotreatment with both siRNAs as determined by the MTT assay. ( a ) Forty-eight hours after siRNA transfection, the number of viable K562 cells decreased significantly ( P o 0.0001). ( b ) Kinetics of growth inhibition of K562 cells following application of 175 pM GFI1B siRNA and 54 pM BCR-ABL siRNA or two scrambled siRNAs and/or without siRNAs is shown. Mean and s.d. are presented. The percentage of viable cells was determined by comparison with untreated or scrambled siRNA-transfected cells. BCR-ABL siRNA, breakpoint cluster region-Abelson murine leukemia oncogene small interfering RNA.CC-BY-NC-ND · From the PDF
Image 4
CC-BY-NC-ND · From the PDF
Figure 3 BCR-ABL and GFI1B gene expression determined by real-time RT-PCR 48 h after siRNA transfection of primary advanced CML cells. ( a ) Forty-eight hours after silencing with both siRNAs in primary cells, the BCR-ABL expression decreased significantly ( P o 0.001). ( b ) Forty-eight hours after silencing with both siRNAs in primary cells, the GFI1B expression decreased significantly ( P o 0.001). Mean and s.d. are presented. Gene expression normalized to GAPDH by real-time RT-PCR. Control was set to 100%. BCR-ABL , breakpoint cluster region-Abelson murine leukemia oncogene; CML, chronic myeloid leukemia; GAPDH , glyceraldehyde-3-phosphate dehydrogenase; RT-PCR, reverse transcription-polymerase chain reaction; siRNA, small interfering RNA.
Figure 3 BCR-ABL and GFI1B gene expression determined by real-time RT-PCR 48 h after siRNA transfection of primary advanced CML cells. ( a ) Forty-eight hours after silencing with both siRNAs in primary cells, the BCR-ABL expression decreased significantly ( P o 0.001). ( b ) Forty-eight hours after silencing with both siRNAs in primary cells, the GFI1B expression decreased significantly ( P o 0.001). Mean and s.d. are presented. Gene expression normalized to GAPDH by real-time RT-PCR. Control was set to 100%. BCR-ABL , breakpoint cluster region-Abelson murine leukemia oncogene; CML, chronic myeloid leukemia; GAPDH , glyceraldehyde-3-phosphate dehydrogenase; RT-PCR, reverse transcription-polymerase chain reaction; siRNA, small interfering RNA.CC-BY-NC-ND · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 32

  1. Deininger MW, Goldman JM, Melo JV . The molecular biology of chronic myeloid leukemia. Blood 2000; 96: 3343–3356. · DOI
  2. Goldmann JM, Melo JV . Chronic myeloid leukemia - advances in biology and new approaches to treatment. N Engl J Med 2003; 349: 1451–1461. · DOI
  3. Simanovsky M, Berlinsky S, Sinai P, Leiba M, Nagler A, Galski H . Phenotypic and gene expression diversity of malignant cells in human blast crisis chronic myeloid leukemia. Differentiation 2008; 76: 908–922. · DOI
  4. Lage H . Potential applications of RNA interference technology in the treatment of cancer. Future Oncol 2005; 1: 103–113. · DOI
  5. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T . Duplexes of 21- nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494–498. · DOI · Paper page
  6. Elmaagacli AH, Koldehoff M, Peceny R, Klein-Hitpass L, Ottinger H, Beelen DW et al. WT1 and BCR-ABL specific small interfering RNA have additive effects in the induction of apoptosis in leukemic cells. Haematologica 2005; 90: 326–334.
  7. Koldehoff M, Kordelas L, Beelen DW, Elmaagacli AH . Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinib. Haematologica 2010; 95: 388–397. · DOI
  8. Tong B, Grimes HL, Ty Yang, Bear SE, Qin Z, Du K et al. The GFI1B proto-oncoprotein represses p21WAF1 and inhibits myloid cell differentation. Mol Cell Bio 1998; 18: 2462–2473. · DOI
  9. Rodel B, Wagner T, Zornig M, Niessing J, Moroy T . The human homologue (GFI1B) of the chicken GFI gene maps to chromosome 9q34.13-A locus frequently altered in hematopoietic diseases. Genomics 1998; 54: 580–582. · DOI
  10. Elmaagacli AH, Koldehoff M, Zakrzewski JL, Steckel NK, Ottinger H, Beelen DW . Growth factor-independent 1B gene (GFI1B) is overexpressed in erythropoietic and megakaryocytic malignancies and increases their proliferation rate. Br J Haematol 2007; 136: 212–219. · DOI
  11. Vassen L, Khandanpour C, Ebeling P, van der Reijden BA, Jansen JH, Mahlmann S et al. Growth factor independent 1b (Gfi1b) and a new splice variant of Gfi1b are highly expressed in patients with acute and chronic leukemia. Int J Hematol 2009; 89: 422–430. · DOI
  12. Koldehoff M, Zakrzewski JL, Klein-Hitpass L, Beelen DW, Elmaagacli AH . Gene profiling of growth factor independence 1B gene (GFI1B) in leukemic cells. Int J Hematol 2008; 87: 39–47. · DOI
  13. Elmaagacli AH, Freist A, Hahn M, Opalka B, Seeber S, Schaefer SW et al. Estimating the relapse stage in chronic myeloid leukaemia patients after allogeneic stem cell transplantation by the amount of BCR-ABL fusion transcripts detected using a new real-time polymerase chain reaction method. Br J Haematol 2001; 113: 1072–1075. · DOI
  14. Specht K, Richter T, Muller U, Walch A, Werner M, Hofler H . Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. Am J Pathol 2001; 158: 419–429. · DOI
  15. Larramendy ML, Niini T, Elonen E, Nagy B, Ollila J, Vihinen M et al. Overexpression of translocation-associated fusion genes of FGFRI, MYC, NPMI, and DEK, but absence of the translocations in acute myeloid leukemia. A microarray analysis. Haematologica 2002; 87: 569–577.
  16. Kourti M, Vavatsi N, Gombakis N, Sidi V, Tzimagiorgis G, Papageorgiou T et al. Expression of multidrug resistance 1 (MDR1), multidrug resistance-related protein 1 (MRP1), lung resistance protein (LRP), and breast cancer resistance protein (BCRP) genes and clinical outcome in childhood acute lymphoblastic leukemia. Int J Hematol 2007; 86: 166–173. · DOI
  17. Scherr M, Battmer K, Winkler T, Heidenreich O, Ganser A, Eder M . Specific inhibition of BCR-ABL gene expression by small interfering RNA. Blood 2003; 101: 1566–1569. · DOI
  18. Novina CD, Sharp PA . The RNAi revolution. Nature 2004; 430: 161–164. · DOI
  19. Koldehoff M, Steckel NK, Beelen DW, Elmaagacli AH . Therapeutic application of small interfering RNA directed against BCR-ABL transcripts to a patient with imatinib-resistant chronic myeloid leukaemia. Clin Exp Med 2007; 7: 47–55. · DOI
  20. Wohlbold L, van der Kuip H, Miething C, Vornlocher HP, Knabbe C, Duyster J et al. Inhibition of BCR-ABL gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571). Blood 2003; 102: 2236–2269. · DOI
  21. Wilda M, Fuchs U, Wössmann W, Borkhardt A . Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference. Oncogene 2002; 21: 5716–5724. · DOI
  22. Merkerova M, Klamova H, Brdicka R, Bruchova H . Targeting of gene expression by siRNA in CML primary cells. Mol Biol Rep 2007; 34: 27–33. · DOI
  23. Withey JM, Marley SB, Kaeda J, Harvey AJ, Crompton MR, Gordon MY . Targeting primary human leukaemia cells with RNA interference: BCR-ABL targeting inhibits myeloid progenitor self-renewal in chronic myeloid leukaemia cells. Br J Haematol 2005; 129: 377–380. · DOI
  24. Pei Y, Tuschl T . On the art of identifying effective and specific siRNAs. Nat Methods 2006; 3: 670–676. · DOI
  25. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of BCR-ABL positive cells. Nat Med 1996; 2: 561–566. · DOI
  26. Perrotti D, Jamieson C, Goldman J, Skorski T . Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest 2010; 120: 2254–2264. · DOI
  27. Perrotti D, Calabretta B . Post-transcriptional mechanisms in BCR/ABL leukemogenesis: role of shuttling RNA-binding proteins. Oncogene 2002; 21: 8577–8583. · DOI
  28. Rumpold H, Webersinke G . Molecular pathogenesis of Philadelphia-positive chronic myeloid leukemia - is it all BCR-ABL? Curr Cancer Drug Targets 2011; 11: 3–19. · DOI
  29. Schulz D, Vassen L, Chow KT, McWhirter SM, Amin RH, Möröy T et al. Gfi1b negatively regulates Rag expression directly and via the repression of FoxO1. J Exp Med 2012; 209: 187–199. · DOI
  30. Ohba H, Zhelev Z, Bakalova R, Ewis A, Omori T, Ishikawa M et al. Inhibition of BCR-ABL and/or c-abl gene expression by small interfering, double-stranded RNAs: cross-talk with cell proliferation factors and other oncogenes. Cancer 2004; 101: 1390–1403. · DOI
  31. Crews LA, Jamieson CH . Chronic myeloid leukemia stem cell biology. Curr Hematol Malig Rep 2012; 7: 125–132. · DOI
  32. Albajar M, Gómez-Casares MT, Llorca J, Mauleon I, Vaqué JP, Acosta JC et al. MYC in chronic myeloid leukemia: induction of aberrant DNA synthesis and association with poor response to imatinib. Mol Cancer Res 2011; 9: 564–576. · DOI · Paper page

Cited by

Sorted by citations

See all 24

Metadata

Authors
Koldehoff, M., Zakrzewski, J. L., Beelen, D. W., & Elmaagacli, A. H.
Venue
Cancer Gene Therapy
Publisher
Springer Science and Business Media LLC
Published
2013-06-21
Volume
20
Issue
7
Pages
421-427
ISSN
  • 0929-1903
  • 1476-5500
DOI
10.1038/cgt.2013.31
Cited by
24
References
1
Language
en
Licence
www.springer.com/tdm (unspecified)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review